People | January 21, 2022
DefiniGen promotes Dr Chris Kirton to CEO
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
They will commercialize molnupiravir in the international markets
Narayanan to lead SeQuent through next phase of consolidation and growth
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
This surpasses the number of approvals supported in 2020
Subscribe To Our Newsletter & Stay Updated
